The dysregulation of HDAC2 expression may affect therapeutic response, suggesting the potential use of HDAC inhibitors in CML patients [22,23,24,25]. The gene discussed is HDAC9; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.